Items tagged with Drug-resistant TB
Drug resistance, HIV hampering fight against TB in Moldova (post)
The health editor of Euractiv, Giedrė Peseckytė, reported back from a press trip to Moldova organised by the Global Fund to Fight AIDS, Tuberculosis and Malaria to explore the challenges that remain in efforts to end the TB epidemic in the country by 2030, as set in the Sustainable Development Goals.
Experts project growth in uptake of shorter, all-oral regimens for drug-resistant TB (post)
A survey of national tuberculosis (TB) program staff members projects consistent global growth in the use of shorter, all-oral drug regimens for drug-resistant TB (DR-TB), but national efforts to ensure the new treatments are accessible to eligible patients are needed, researchers reported late last week in PLOS One.
RESIST-TB January 2024 newsletter (post)
RESIST-TB released its January 2024 newsletter with the latest updates and research publications on drug-resistant TB.
Welch Foundation grant supports research on drug-resistant TB (post)
With a $300,000 grant, the Welch Foundation is supporting University of Texas at Arlington (UTA) research into why some types of Mycobacterium tuberculosis (Mtb), the bacteria that causes the lung disease tuberculosis (TB), do not respond to treatments.
RESIST-TB February 2024 newsletter (post)
RESIST-TB released its February 2024 newsletter with the latest updates and research publications on drug-resistant TB.
Research links prison time with increase of TB (post)
Tuberculosis, the main cause of death due to a single pathogen globally, causes more than 1.5 million deaths each year. New research from the University of Cincinnati finds that being in prison or being a former prisoner is responsible for high rates of multidrug-resistant (MDR) TB.
Drug-resistant TB responds rapidly to bedaquiline-based second-line therapy (post)
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, according to researchers at Weill Cornell Medicine in New York and GHESKIO in Haiti. Second-line medications are those that are given when one or more of the drugs given first for the disease are not effective. The research could have implications for shortening the duration of treatment for drug-resistant TB, which currently requires medications for up to 2 years, while those with drug-sensitive TB complete treatment in about 6 months.
RESIST-TB March 2024 newsletter (post)
RESIST-TB released its March 2024 newsletter with the latest updates and research publications on drug-resistant TB.
Australian Government grants TB Alliance an award to help bolster clinical research and improve access to new treatments for drug-resistant TB (post)
CANBERRA (25 March 2024)—The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Alliance through its Product Development and Access Partnerships program. The funding will contribute toward the completion of the NC-009 Pan-Phase 2 clinical trial and also help establish and sustain the Peer-to-Peer Learning for Innovative Cures (PeerLINC) Knowledge Hub in Manila, which will disseminate best practices to help speed the programmatic implementation of innovative, effective tuberculosis treatments, including the World Health Organization (WHO) recommended six-month, all-oral BPaL/M regimens for drug-resistant tuberculosis (DR-TB).
Brazil: Isoniazid resistance linked with TB deaths (post)
In 2022, more than 78,000 new cases of tuberculosis (TB) were reported in Brazil, with an incidence of 36.3 cases per 100,000 inhabitants. According to researchers from the Regional Prospective Observational Research for Tuberculosis (RePORT)-Brazil consortium, the country could improve the control of this infection if all patients were subjected to a sensitivity test capable of early detection of resistance not only to rifampicin, but also to isoniazid, before starting treatment. A study by the consortium published this year in Open Forum Infectious Diseases found that monoresistance to isoniazid predicted unfavorable outcomes at the national level.
Page 84 of 117 · Total posts: 0
←First 83 84 85 Last→